Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

0.8441 UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle ↗

February 01, 2024

On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a...

Via Benzinga

2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge ↗

February 01, 2024

The global population is experiencing a scary increase in colorectal cancer, especially among young people. Colorectal cancer (CRC) diagnoses have been steadily rising since the 1990s; in 1995 the...

Via Benzinga

Topics Death

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

January 11, 2024

From Mainz BioMed NV

Via GlobeNewswire

2024 Marks a New Era Of Pharmaceutical Innovation ↗

January 09, 2024

With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned...

Via Benzinga

The Latest Analyst Ratings for Mainz Biomed ↗

November 20, 2023

Via Benzinga

Mainz Biomed Provides Year-End Corporate Review 2023

January 09, 2024

From Mainz BioMed NV

Via GlobeNewswire

2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer ↗

December 29, 2023

During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc.

Via Benzinga

Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study ↗

December 19, 2023

Via Benzinga

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

December 19, 2023

Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and...

From Mainz BioMed NV

Via GlobeNewswire

Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

December 12, 2023

From Mainz BioMed NV

Via GlobeNewswire

Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

December 05, 2023

Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

December 05, 2023

Via Benzinga

While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer ↗

December 05, 2023

Obesity has been linked to development of a range of diseases and unfortunately, cancer. More specifically, the National Cancer Institute estimated that colorectal cancer is 1.3 times more likely in...

Via Benzinga

Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

December 05, 2023

From Mainz BioMed NV

Via GlobeNewswire

Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast

November 29, 2023

From Mainz BioMed NV

Via GlobeNewswire

Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference

November 20, 2023

From Mainz BioMed NV

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 16, 2023

Via Benzinga

Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 16, 2023

From Mainz BioMed NV

Via GlobeNewswire

Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering

November 15, 2023

From Mainz BioMed NV

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 14, 2023

Via Benzinga

Crude Oil Gains Over 1%; US Budget Deficit Narrows For October ↗

November 13, 2023

U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 50 points on Monday. The Dow traded up 0.16% to 34,337.33 while the NASDAQ fell 0.11% to 13,783.41. The S&P 500...

Via Benzinga

Topics Stocks

Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

November 13, 2023

Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 13, 2023

Via Benzinga

Why Mainz Biomed (MYNZ) Stock Is Getting Hammered ↗

November 13, 2023

Mainz Biomed NV (NASDAQ: MYNZ) shares are trading lower by 46% to $1.21 during Monday's session has entered a securities purchase agreement with institutional investors to raise $5 million through a

Via Benzinga

Dow Surges 100 Points; Tenax Therapeutics Shares Spike Higher ↗

November 13, 2023

U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining around 100 points on Monday. The Dow traded up 0.33% to 34,397 while the NASDAQ fell 0.06% to 13,790. The S&P 500...

Via Benzinga

Topics Stocks

US Stocks Fall; Tyson Foods Posts Upbeat Earnings ↗

November 13, 2023

U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 100 points on Monday. Following the market opening Monday, the Dow traded down 0.08% to 34,254.53 while the NASDAQ fell...

Via Benzinga

Topics Stocks

Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering

November 13, 2023

From Mainz BioMed NV

Via GlobeNewswire

Mainz Biomed Partners With Liquid Biosciences In Exclusive Relationship To Harness The Power Of Artificial Intelligence (AI) To Develop Next-Generation Colorectal Screening Test ↗

November 13, 2023

The integration of Artificial Intelligence (AI) in biotechnology is rapidly gaining momentum, revolutionizing the field of life sciences. AI technologies, such as machine learning and deep learning...

Via Benzinga

Topics Artificial Intelligence

Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test

November 09, 2023

Collaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing

From Mainz BioMed NV

Via GlobeNewswire

Mainz Biomed’s (NASDAQ: MYNZ) ColoFuture Study Reveals “Groundbreaking Results”: ColoAlert® Raises The Bar For Colorectal Cancer Detection

November 08, 2023

--News Direct--

Via News Direct

Topics Death

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.